ABSTRACT
INTRODUCTION
Breast tumours rank first in incidence and third as cause of mortality among various malignant diseases in Hong Kong females. 1 Globally, breast carcinoma is the most frequent malignancy among women in terms of incidence and mortality rates in both developed and developing countries. 2 These are detected with increasing frequency by breast screening programmes 3, 4 in symptomatic and high-risk patients. Conventional percutaneous biopsy methods such as fine-needle aspiration, core biopsy, or open surgical excision are often used to obtain tissue diagnoses for clinically palpable and imaging-detected lesions. Most are performed by ultrasound guidance, but some mammographic microcalcifications and parenchymal deformities are not detected sonographically. Stereotactic technique is therefore required to biopsy these suspicious lesions. 5 Stereotactic-guided vacuum-assisted breast biopsy (VAB) has therefore gained popularity as a minimally invasive technique for evaluation of non-palpable breast lesions with microcalcifications. Percutaneous VAB devices have been shown to have many advantages over conventional percutaneous biopsy methods. 6 A larger amount of tissue with multiple contiguous specimens can be obtained with single insertion of a biopsy needle. The higher-quality specimen retrieved reduces rates of false-negative results of cancer detection and rates of histological underestimation. [7] [8] [9] [10] [11] VAB is also a recognised method for complete excision of benign breast lesions. 12, 13 However, analytical studies on the utility of VAB in Asian women are relatively rare, who often have smaller or thinner breasts than western women. Therefore, the aim of this study was to evaluate the safety and efficacy of a 9-gauge VAB system performed in Asian patients in a conventional mammography unit of a regional hospital in Hong Kong.
METHODS
A retrospective review of 41 consecutive patients who received stereotactic-guided VAB of microcalcifications between September 2008 and April 2013 in a regional hospital was conducted. Data on patients' demographics, pre-procedural mammographic studies, biopsy-related technical factors (including the type of needle applied, approach used, and marker deployment), technical success rate, associated complications, and pathological outcomes were evaluated.
Patient Demographics
The patient age ranged from 37 to 71 years with a mean age of 52 years. The latent interval between the mammogram examination and VAB ranged from 11 to 213 days, with a mean of 69 days and a median of 57 days. All patients were free from underlying bleeding disorders and were not on antithrombotic therapy.
Pre-procedural Mammographic Data
The pre-procedural mammographic data of all patients with microcalcifications referred for VAB were evaluated. The microcalcifications were graded by using a 5-point scale with reference to the Royal College of Radiologists Breast Group breast imaging classification 14 to indicate the level of suspicion for malignancy and to act as a guide for the need of needle biopsy. Category 1 (normal) or 2 (benign) lesions did not require sampling, while category 3 (indeterminate / probably benign), 4 (suspicious of malignancy), and 5 (highly suspicious of malignancy) lesions required percutaneous needle breast biopsy due to their greater association with malignancy, ranging from 0.5% to 2%, 33% to 50%, and 90%, respectively. 15 Locations of the microcalcifications were also documented.
Biopsy Procedures and Post-procedural Assessment
VAB was performed with a 9-gauge ATEC Breast Biopsy System (Suros Surgical Systems Inc., Indianapolis [IN] , USA) [ Figure 1 ] in an upright method, using an add-on stereotactic device attached to a digital mammography unit (Figure 2 ). Biopsy needles with an aperture of either 20 mm or 12 mm (for thinner breasts) were used. Thin breasts with thickness of less than the combined length of the needle biopsy bevel and the needle tip dead space were rendered not feasible for VAB. The procedures were performed with lateralmedial or cranial-caudal approach depending on the position of the microcalcifications (Figure 3) . During the procedure, the breasts were compressed in accordance with patients' endurance to maintain sufficient fixation. Efforts were made to ensure the breast did not move or slip during the procedure. After localisation of the microcalcifications (Figure 4) , local superficial and deep anaesthesia was administered by injecting a mixture of 5 ml 2% lignocaine plus 5 ml diluted adrenaline (1 ml [1 in 10 000] adrenaline mixed with 9 ml normal saline) at the site marked by stereotactic guidance. A small skin incision was then made for needle insertion. The biopsy needle was inserted perpendicular to the compression paddle and positioned by stereotactic guidance. A pair The vacuum system. The biopsy needle is connected to a vacuum system to facilitate biopsy of breast tissue. Saline lavage of the breast biopsy cavity is also possible to minimise the risk of haematoma formation. in the biopsied breast tissues ( Figure 6 ). An inert titanium metallic marker was then deployed into the breast for biopsy-site identification for small lesions and microcalcification clusters that were completely removed ( Figure 7 ). Assessments for removal of microcalcifications, possible haematoma formation, and accurate metallic marker deployment were made in post-procedural mammography. After removal of the biopsy system, localised compression of the breast for 15 to 30 minutes by a dedicated nursing colleague was performed for every patient until the bleeding stopped.
Technical Success
Technical success was defined as the presence of microcalcifications in the specimen radiograph without the need of a repeated biopsy.
Associated Complications
Procedure-related complications were assessed with a systematic checklist by a designated radiologist and nursing colleague. All patients underwent reassessment immediately, after 4 hours, and 1 day after the VAB procedure. Evidence of bleeding, bruising, haematoma formation, induration of breast tissue and systemic symptoms such as vasovagal syncope was documented.
Haematomas were classified as non-clinically significant or clinically significant. 16 A non-clinically significant haematoma was defined as an asymptomatic haematoma visible only on mammograms, a mildly tender haematoma with pain well controlled by analgesics (such as paracetamol), and a haematoma that required no additional surgical intervention. A clinically significant haematoma was defined as that which required additional surgical intervention or percutaneous drainage, and which caused severe post-biopsy pain with no response to analgesics.
Pathological Outcomes
All histological results of the VAB were traced and correlated with the mammographic findings. For patients who underwent subsequent surgery, the final surgical histological findings were assessed and compared with the VAB results. Histological underestimate was defined as an upgrade of a malignant pathological VAB finding in subsequent surgical excision. For example, a VAB specimen that yielded ductal carcinoma in-situ (DCIS) but showed the presence of an invasive component in excisional surgical biopsy would be a histological underestimate.
RESULTS

Preprocedural Mammographic Data
A total of 41 consecutive patients with 43 lesions were included in the study, with two patients having bilateral lesions. The grading of the microcalcifications is shown in Table 1 , with the majority being graded as indeterminate (90.7%).
The locations of the microcalcifications are shown in Figure 7 . Post-procedural radiograph. An inert titanium metallic marker is deployed into the breast for biopsy-site identification, and the position of the marker was counterchecked in the postprocedural radiograph. 
Biopsy Procedures
A needle aperture of 12 mm was used in 25.6% (n=11) of the cases, and a needle aperture of 20 mm was employed in the remaining 74.4% (n=32) of patients. The lateral-medial approach was used in all but one case (97.7%, n=42); the cranial-caudal approach was used in one case (2.3%). A metallic marker was deployed in 34 (79.1%) cases.
As microcalcifications were found in all the post-biopsy specimen radiographs and none of the cases required repeated biopsy, the technical success rate rendered was 100%.
Associated Complications
Except for one patient who had vasovagal syncope, none of the patients complained of systemic symptoms during the procedure. Most reported complications were minor and included mild bleeding (n=5), clinically nonsignificant haematomas (n=3), mild bruising (n=4), and breast induration (n=1); all symptoms were resolved spontaneously. No clinically significant haematoma was noted and no surgical intervention was required for any of the cases.
Histology Results
The VAB histology was benign in 62.8% (n=27) of the cases; 37.2% (n=16) were malignant or malignancyassociated lesions. The benign microcalcifications were predominantly due to fibrocystic change (n=13) and there were various histopathological findings in the malignant or malignancy-associated lesions. Findings are summarised in Table 3 .
Correlation of pre-procedural mammographic findings with VAB histology was made and is summarised in Abbreviations: IDC = invasive ductal carcinoma; DCIS = ductal carcinoma in situ; ADH = atypical ductal hyperplasia; ALH = atypical lobular hyperplasia; ACCH = atypical columnar cell hyperplasia. * Multiple benign diagnoses are present in seven patients.
hyperplasia (n=1) and atypical lobular cell hyperplasia (n=1). The remaining 25 (64.1%) cases had no malignant pathology.
Seven of the VAB-diagnosed malignant or malignancyassociated lesions were surgically excised. The rest of these patients either defaulted follow-up or refused further surgical intervention and were excluded. Correlation of histology results in excisional biopsies and VAB was conducted ( Abbreviations: ADH = atypical ductal hyperplasia; DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma; VAB = vacuumassisted breast biopsy. In summary, there were 7 true positive cases, no false positive case, 26 true negative cases, and 1 false negative case. The sensitivity for VAB was calculated to be 87.5%, while the specificity was 100%. The positive predictive value was 100%, while the negative predictive value was 96.3% (Table 6 ).
There were 10 patients with previously treated malignant breast disease. A relatively high proportion of these patients (70%, n=7) had recurrence of malignant or malignancy-associated pathology: one patient had recurrence at the same site while the remaining patients had recurrent disease in the contralateral breast (Table 7) .
DISCUSSION
Stereotactic-guided VAB has recently evolved as a minimally invasive technique for evaluation of nonpalpable breast lesions with microcalcifications. 8, 17, 18 Stereotaxis utilises co-ordinates defined from oblique radiographs to determine accurate needle placement, which is the basis for stereotactic-guided breast biopsies. 19 The lesion is localised in three dimensions using two angled stereotactic images taken at 15° on either side of the direction of the scout image. The target for accurate needle placement is then calculated by the computer software. 20 The application of vacuum assistance in breast biopsy allows the use of larger gauge probes than conventional core biopsy needles, thus helping to obtain a larger amount of breast tissue for histopathological examination. 19 It involves the incorporation of a vacuum chamber to draw tissue into the cutting needle where the sample is taken. Multiple contagious samples can be retrieved by rotating the biopsy needle in a different direction with a single needle puncture.
Various types of VAB devices are available, each with different strengths and weaknesses. 19 The first VAB device in the market was the Mammotome (Ethicon
Surgically proven malignant lesion
No surgically proven malignant lesion VAB-positive for malignant lesion 7 0 Positive predictive value = 100% VAB-negative for malignant lesion 1 26 Negative predictive value = 96.3% Sensitivity = 87.5% Specificity = 100% Table 6 . Summary of sensitivity, specificity, positive predictive value and negative predictive value of vacuum-assisted breast biopsy (VAB).
Endo-Surgery, Inc., Cincinnati [OH], USA) in 1995. ATEC Breast Biopsy System (Suros Surgical Systems Inc.), which was used in our patients, is a second generation of VAB apparatus that automatically and continuously irrigates the biopsy cavity in a closed system. It can also be set to continuously acquire specimens from pre-programmed positions in the breast. Together with a large needle (9-gauge), this VAB technique can retrieve a larger amount of breast tissue for more extensive sampling and possible complete removal of some clusters of microcalcifications. It has been shown that VAB outperforms biopsy with core biopsy needle in terms of larger specimen size and higher calcification retrieval rate; and lower targeting error, false negative rate, underestimation rate, and the need for re-biopsy or further multi-treatment surgery.
19,21
The VAB procedure can be performed using an uprighttype stereotactic mammography unit or a pronetype biopsy table with similar efficacy and calcium retrieval rates. 22 The upright units modify existing mammographic equipment temporarily and may be used with a special chair that enables the patient to lie flat in the horizontal decubitus position to reduce the rate of vasovagal syncope. For dedicated pronetype stereotactic apparatus, the patient lies face down on the biopsy table and the breast falls through a hole in the table. The breast is then compressed against a mammographic plate with a lateral-medial or cranialcaudal projection depending on the location of the target microcalcifications. The breast tissue can be sampled after the target area is localised with stereotactic guidance. 20 Our technical success rate was 100% with microcalcifications present in all specimen radiographs and no patient required repeated biopsy. In a previously published study, a higher calcification retrieval rate was achievable with the use of larger calibre biopsy needle. [23] [24] [25] According to Jackman and Rodriguez-Soto, 24 technical failure of calcification retrieval was noted in 4% of lesions using 14-gauge vacuum biopsy needle, and in only 1% of lesions with the use of 11-gauge vacuum biopsy. These data suggest that 9-gauge biopsy needle may be associated with a higher technical success rate than 11-or 14-gauge needle. In line with this principle, our study found that 9-gauge needle was a satisfactory instrument in VAB to ensure adequate sampling of breast tissue for accurate histological diagnosis.
A high level of concordance between preoperative and surgical diagnoses is important to minimise surgical procedures and avoids misdiagnosis. 26 Among the operated cases for VAB-diagnosed malignant or malignancy-associated lesions in our study, the majority (71.4%, n=5/7) demonstrated concordance between postoperative and VAB histology. The sensitivity, specificity, positive and negative predictive values were shown to be satisfactory in this study, and did not deviate significantly from values reported in other published results. 10, 20, 22, [27] [28] [29] Underestimation was observed in only one case which was upgraded from DCIS to invasive carcinoma; this finding is not substantially different Table 7 . Correlation of vacuum-assisted breast biopsy-diagnosed malignant or malignancy-associated histopathology in patients with prior malignant breast disease.
Abbreviations: ADH = atypical ductal hyperplasia; DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma.
from that in other studies. 20 These data suggest that VAB is an effective means to characterise the nature of lesions for planning further surgical management in patients with breast microcalcifications.
In our study, a relatively high percentage of patients (70%) with prior breast tumour had recurrence of malignant or malignancy-associated pathology. This finding suggests that VAB should be performed at a lower threshold for microcalcifications in patients with prior history of malignant breast disease, disregarding the site of the microcalcifications (ipsilateral or contralateral breast).
Complication rates reported in previously published studies were low, and included vasovagal reactions, mild bruising, haematoma, and abscess formation. 19, 22 The rate of requirement for surgical drainage of a haematoma or abscess was around 0.1%. 23, 30 A large centre review indicated that only 0.17% of patients developed mastitis requiring antibiotics. 31 Our study showed that VAB was a safe procedure with no clinically significant haematoma formation or substantial complication in any patient. This was in concordance with published reports concerning the risk of haematoma formation during core needle biopsy of the breast. 16, 32, 33 The vacuum applied throughout the procedure was useful for suction of blood out of the biopsy cavity to decrease haematoma formation. 20 For non-clinically significant haematoma, supportive therapeutic measures with pressure bandage, ice packs, simple analgesia with paracetamol, and short-term clinical follow-up are often all that are necessary. 16 Our routine reassessment 4 hours and 1 day after the biopsy procedure served as a satisfactory survey of complications. No patient reported having significant complications after the reassessment.
There were several limitations to this study. As a retrospective study, it had its inherent limitations. The sample size was relatively small and the study was performed at a single institution by a selected group of breast radiologists; thus, the results might not be readily generalised to other practices. A longer followup period for benign cases was also desirable to obtain a higher accuracy of false-negative rate. Nevertheless, this study served the purpose of a pilot study in evaluating the safety and efficacy of VAB, and largerscale studies involving a bigger sample or multicentre evaluation would be useful for further assessment of VAB procedures.
CONCLUSION
Stereotactic-guided VAB with a 9-gauge biopsy system is a safe and effective method for evaluation of nonpalpable breast lesions with microcalcifications on mammography. The procedure is the most reliable alternative to surgical breast biopsy. In particular, VAB should be performed at a lower threshold for microcalcifications in patients with prior history of malignant breast disease.
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